What is the recommended empiric treatment for hospital‑acquired pneumonia, including coverage for gram‑negative and MRSA organisms?

Hospital-Acquired Pneumonia: Empiric Treatment Algorithm

Empiric treatment for hospital-acquired pneumonia must be stratified by mortality risk and MRSA risk factors, with all patients requiring coverage for gram-negative organisms including Pseudomonas aeruginosa, and MRSA coverage added based on specific risk criteria. 1

Risk Stratification Framework

Low Mortality Risk WITHOUT MRSA Risk Factors

Use monotherapy with a single antipseudomonal agent: 1, 2

• Piperacillin-tazobactam 4.5 g IV q6h (preferred for broad gram-negative and MSSA coverage) 1
• OR Cefepime 2 g IV q8h 1
• OR Levofloxacin 750 mg IV daily 1
• OR Imipenem 500 mg IV q6h 1
• OR Meropenem 1 g IV q8h 1

These agents provide adequate coverage for Pseudomonas aeruginosa, other gram-negative bacilli, and methicillin-sensitive S. aureus (MSSA). 1

Low Mortality Risk WITH MRSA Risk Factors

Use the same monotherapy options PLUS add MRSA coverage: 1, 2

MRSA coverage options: 1

• Vancomycin 15 mg/kg IV q8-12h (target trough 15-20 mg/mL; consider loading dose of 25-30 mg/kg for severe illness) 1
• OR Linezolid 600 mg IV q12h 1

MRSA risk factors include: 1

• IV antibiotic use within the prior 90 days 1
• Treatment in a unit where MRSA prevalence among S. aureus isolates is unknown or >20% 1
• Prior MRSA colonization or infection 1

High Mortality Risk OR Recent IV Antibiotics

Use dual antipseudomonal therapy PLUS MRSA coverage: 1, 2

High mortality risk is defined as: 1

• Need for ventilatory support due to pneumonia 1
• Septic shock 1

• 15% predicted mortality 1

Dual antipseudomonal regimen (choose TWO from different classes, avoid two β-lactams): 1

β-lactam options (choose ONE): 1

• Piperacillin-tazobactam 4.5 g IV q6h 1
• Cefepime 2 g IV q8h 1
• Ceftazidime 2 g IV q8h 1
• Imipenem 500 mg IV q6h 1
• Meropenem 1 g IV q8h 1
• Aztreonam 2 g IV q8h 1

PLUS a second agent (choose ONE): 1

• Levofloxacin 750 mg IV daily 1
• Ciprofloxacin 400 mg IV q8h 1
• Amikacin 15-20 mg/kg IV daily 1
• Gentamicin 5-7 mg/kg IV daily 1
• Tobramycin 5-7 mg/kg IV daily 1

PLUS MRSA coverage: 1

• Vancomycin 15 mg/kg IV q8-12h (target trough 15-20 mg/mL) 1
• OR Linezolid 600 mg IV q12h 1

Special Populations Requiring Dual Antipseudomonal Coverage

Patients with structural lung disease ALWAYS require two antipseudomonal agents regardless of other risk factors: 1, 2

• Bronchiectasis 1, 2
• Cystic fibrosis 1, 2

Additional indications for dual coverage: 1

• Gram stain showing numerous predominant gram-negative bacilli 1
• Known colonization with resistant gram-negative organisms 1

Critical Pitfalls to Avoid

Never use aminoglycosides as monotherapy for HAP, even when susceptibility testing suggests activity, as this is associated with treatment failure. 1, 2

Never combine two β-lactam antibiotics (e.g., piperacillin-tazobactam plus cefepime), as they have overlapping mechanisms and provide no synergy. 1, 2 The exception is aztreonam, which can be combined with another β-lactam because it targets different sites within the bacterial cell wall. 1

Do not omit MSSA coverage when MRSA coverage is not indicated—the chosen antipseudomonal agent must have MSSA activity. 1 If using aztreonam (which lacks gram-positive activity), you must add a separate agent for MSSA coverage. 1

Do not use third-generation cephalosporins (ceftriaxone, cefotaxime) for HAP, as they lack adequate antipseudomonal activity and increase risk of Clostridioides difficile infection. 1 These agents are appropriate only for low-risk community-acquired pneumonia, not hospital-acquired pneumonia. 1

Penicillin Allergy Considerations

For patients with documented severe penicillin allergy: 3

• Aztreonam 2 g IV q8h (negligible cross-reactivity with penicillins) 3
• PLUS vancomycin or linezolid for MRSA and MSSA coverage 3
• PLUS ciprofloxacin 400 mg IV q8h or an aminoglycoside if dual antipseudomonal coverage is needed 3

Avoid cephalosporins in documented penicillin allergy due to 1-10% cross-reactivity risk. 3

Pharmacokinetic Optimization

Consider extended infusions of β-lactams (infusing over 3-4 hours rather than 30 minutes) to optimize time-dependent killing and maximize drug exposure, particularly in critically ill patients. 2

Vancomycin therapeutic monitoring: 1, 3

• Measure trough levels on day 3-4 of therapy 3
• Target trough concentration of 15-20 mg/mL 1, 3
• Use loading dose of 25-30 mg/kg for severe illness 1, 3

Treatment Duration and De-escalation

Treat for 7 days in most patients, including those with glucose non-fermenting gram-negative organisms like Pseudomonas. 4

Base all empiric regimens on local antibiogram data whenever possible, as resistance patterns vary significantly between institutions. 2, 4, 5 Single antipseudomonal coverage is acceptable when local data demonstrate that ≥90% of gram-negative isolates are susceptible to the chosen agent. 1, 4

De-escalate therapy once culture results and susceptibilities are available to narrow coverage and reduce selection pressure for resistance. 5